SEC Form 4 · accession 0000899243-17-016675
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tyler Dylan-Hyde
Officer — Chief Legal Officer
Period of report
Jun 15, 2017
Accepted (ET)
Jun 19, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $14.43 | Jun 15, 2017 | A | 65,000 | A | — | Jun 15, 2027 | Common Shares | 65,000 | 65,000 | D |
Explanation of responses
- F1This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017.